Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Nvidia Corp (NVDA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Nvidia Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.01 (market cap $39.89B), while Nvidia Corp trades at $207.78 (market cap $5.11T). The key difference: Nvidia Corp is far larger — about 128.1× Alnylam Pharmaceuticals, Inc.'s market cap, and Nvidia Corp pays a 0.47% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | NVDA | |
|---|---|---|
Market Cap | $39.89B | $5.11T |
Sector | Health | Technology |
52-Week High | $491.22 | $235.75 |
52-Week Low | $278.09 | $164.07 |
Enterprise Value | $38.15B | $5.04T |
Dividend Yield | — | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
NVIDIA (NVDA) trades at $210.96, up 4.07% today, with a bullish technical signal from moving averages. The company reported robust fundamentals, including a 130.5B revenue in 2025 and a net income margin of 62.97%. Recent earnings beats and strong cash flow from operations of $64.09B highlight operational strength. Analyst consensus is strongly bullish with a $324.95 price target, though the stock faces risks from competition and market volatility.
Outlook remains positive driven by AI chip demand, with revenue projected to reach $253.5B in 2026. However, investors should weigh high valuation multiples like a P/E of 32.31 and competitive pressures. The stock offers significant upside per analyst targets but requires monitoring of execution risks and macroeconomic factors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Nvidia Corp
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →
